全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Nodular Pulmonary Amyloidosis with Interstitial Lung Disease—Case Report and Literature Review

DOI: 10.4236/ojts.2024.142004, PP. 40-45

Keywords: Nodular Amyloidosis, Interstitial Lung Disease, Immunomodulatory Drugs

Full-Text   Cite this paper   Add to My Lib

Abstract:

Amyloidosis is a rare spectrum of disease which involves deposition of misfolded extracellular proteins (amyloids) in various body organs leading to progressive organ dysfunction. Clinical presentation can be variable depending on the organ involved and type of protein. Amyloidosis can be classified based on quantity, type, and location of these proteins. Amyloid light-chain amyloidosis develops in the bone marrow, producing abnormal forms of light-chain proteins, which cannot be broken down. These proteins transform into amyloid fibrils and form amyloid deposits in different organs. Pulmonary amyloidosis is uncommonly diagnosed since it is rarely symptomatic. Diagnosis of pulmonary amyloidosis is usually made in the setting of systemic amyloidosis; however, it may present as localised pulmonary disease. Localized pulmonary Amyloidosis can present as nodular, cystic, or tracheobronchial amyloidosis. Depending on the degree of the interstitial involvement, it may affect alveolar gas exchange and cause respiratory symptoms. This is a case of a 47-year-old female with background history of interstitial lung disease presenting with progressive shortness of breath. Computed tomography scan revealed bilateral pulmonary nodules. The patient was referred to our thoracic surgery team with the suspicion of bronchogenic malignancy with metastasis. Diagnostic video assisted wedge resection was performed for this patient, and histology confirmed pulmonary amyloidosis of nodular type. Amyloid deposition simulates both inflammatory and neoplastic conditions. Definitive diagnosis requires biopsy confirmation therefore early detection and commencing the patient on appropriate treatment pathway may help in symptomatic relief and better outcome.

References

[1]  Ophanet. AL amyloidosis.
https://www.orpha.net/en/disease/detail/85443#
[2]  Milani, P., Basset, M., Russo, F., Foli, A., Palladini, G. and Merlini, G. (2017) The Lung in Amyloidosis. European Respiratory Review, 26, Article ID: 170046.
https://doi.org/10.1183/16000617.0046-2017
[3]  Moy, L.N., Mirza, M., Moskal, B., Asado, N., Shah, B. and Bitran, J. (2022) Pulmonary AL amyloidosis: A Review and Update on Treatment Options. Annals of Medicine & Surgery, 80.
https://doi.org/10.1016/j.amsu.2022.104060
[4]  Khoor, A., Myers, J.L., Tazelaar, H.D. and Kurtin, P.J. (2004) Amyloid-Like Pulmonary Nodules, Including Localized Light-Chain Deposition: Clinicopathologic Analysis of Three Cases. American Journal of Clinical Pathology, 121, 200-204.
https://doi.org/10.1309/3GECPW2402F6V8EK
[5]  Düzgün, N., Kurtipek, E., Esme, H., Eren Karanis, M.İ. and Tolu, İ. (2015) Pulmonary Hyalinizing Granuloma Mimicking Metastatic Lung Cancer. Case Reports in Pulmonology, 2015, Article ID: 610417.
https://doi.org/10.1155/2015/610417
[6]  Kesici, B., Toros, A.B., Bayraktar, L. and Dervisoglu, A. (2014) Sarcoidosis Incidentally Diagnosed: A Case Report. Case Reports in Pulmonology, 2014, Article ID: 702868.
https://doi.org/10.1155/2014/702868
[7]  Grogg, K.L., Aubry, M.C., Vrana, J.A., Theis, J.D. and Dogan, A. (2013) Nodular Pulmonary Amyloidosis Is Characterized by Localized Immunoglobulin Deposition and Is Frequently Associated with an Indolent B-Cell Lymphoproliferative Disorder. American Journal of Surgical Pathology, 37, 406-412.
https://doi.org/10.1097/PAS.0b013e318272fe19
[8]  Rajagopala, S., Singh, N., Gupta, K. and Gupta, D. (2010) Pulmonary Amyloidosis in Sjogren’s Syndrome: A Case Report and Systematic Review of the Literature. Respirology, 15, 860-866.
https://doi.org/10.1111/j.1440-1843.2010.01772.x
[9]  Al-Umairi, R.S., Al-Lawati, F. and Al-Busaidi, F.M. (2018) Nodular Pulmonary Amyloidosis Mimicking Metastatic Pulmonary Nodules: A Case Report and Review of the Literature. Sultan Qaboos University Medical Journal, 18, e393-e396.
https://doi.org/10.18295/squmj.2018.18.03.023
[10]  Jones, N.F., Hilton, P.J., Tighe, J.R. and Hobbs, J.R. (1972) Treatment of “Primary” Renal Amyloidosis with Melphalan. The Lancet, 300, 616-619.
https://doi.org/10.1016/S0140-6736(72)93014-0
[11]  Baker, K.R. and Rice, L. (2012) The Amyloidoses: Clinical Features, Diagnosis and Treatment. Methodist DeBakey Cardiovascular Journal, 8, 3.
https://doi.org/10.14797/mdcj-8-3-3
[12]  Palladini, G., Milani, P. and Merlini, G. (2020) Management of AL Amyloidosis in 2020. Blood, 136, 2620-2627.
https://doi.org/10.1182/blood.2020006913
[13]  Bal, S. and Landau, H. (2021) AL Amyloidosis: Untangling New Therapies. Hematology, 2021, 682-688.
https://doi.org/10.1182/hematology.2021000305
[14]  NICE (2023) Daratumumab with Bortezomib and Dexamethasone for Previously Treated Multiple Myeloma.
https://www.nice.org.uk/guidance/ta897/evidence
[15]  Rech, J., Arnulf, B., De Margerie-Mellon, C., Talbot, A., Malphettes, M., Vignon, M., et al. (2019) Lower Respiratory Tract Amyloidosis: Presentation, Survival and Prognostic Factors. A Multicenter Consecutive Case Series. American Journal of Hematology, 94, 1214-1226.
https://doi.org/10.1002/ajh.25608

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133